1887

Abstract

drug resistance to antibiotics is a serious situation that has drawn greater attention to immunotherapy and prophylaxis. Peptidoglycan (PGN) is a common and conserved component of the cell wall of Gram-positive bacteria such as . However, PGN, as a thymus-independent antigen, cannot be considered a vaccine candidate because of its very weak immunogenicity. In this study we have attempted to enhance the immunogenicity of PGN by identifying a PGN peptide mimic sequence that would act as a thymus-dependent antigen. Several peptide sequences were obtained from a phage display peptide library using a mAb against PGN, and a 12-mer linear single peptide (Sp-31) and a four-branch multiple antigen peptide (MAP) (MAP-P31) were synthesized. Both Sp-31 and MAP-P31 were shown to bind directly to anti-PGN mAb and a polyclonal antibody against . These peptides could also inhibit the binding of PGN to a mAb against PGN. Furthermore, MAP-P31 was able to provoke an effective secondary antibody response in mice to PGN and to cell-wall fragments isolated from , , and by sonication. In addition, the MAP-P31 antiserum showed a potent bactericidal or bacteriostatic activity against in the presence and absence of complement . Importantly, immunization with MAP-P31 significantly prolonged the survival and enhanced bacterial clearance in BALB/c mice challenged with live . In addition, the serum IgG-type antibodies against PGN persisted in mice, demonstrating that MAP-P31, as a peptide mimicking epitopes on PGN, provokes an effective secondary or memory antibody response, which can only be induced by a thymus-dependent antigen and which protects against infection with . These results suggest that MAP-31 may be a novel vaccine candidate against .

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.028647-0
2011-07-01
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/7/995.html?itemId=/content/journal/jmm/10.1099/jmm.0.028647-0&mimeType=html&fmt=ahah

References

  1. Baker M. . ( 2006; ). Anti-infective antibodies: finding the path forward. . Nat Biotechnol 24:, 1491–1493. [CrossRef].[PubMed].
    [Google Scholar]
  2. Beninati C. , Arseni S. , Mancuso G. , Magliani W. , Conti S. , Midiri A. , Biondo C. , Polonelli L. , Teti G. . ( 2004; ). Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide. . J Immunol 172:, 2461–2468.[PubMed].[CrossRef]
    [Google Scholar]
  3. Buzzola F. R. , Barbagelata M. S. , Caccuri R. L. , Sordelli D. O. . ( 2006; ). Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice. . Infect Immun 74:, 3498–3506. [CrossRef].[PubMed].
    [Google Scholar]
  4. Datta K. , Lees A. , Pirofski L. A. . ( 2008; ). Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. . Clin Vaccine Immunol 15:, 1176–1187. [CrossRef].[PubMed].
    [Google Scholar]
  5. Falklind-Jerkérus S. , Felici F. , Cavalieri C. , Lo Passo C. , Garufi G. , Pernice I. , Islam M. M. , Qadri F. , Weintraub A. . ( 2005; ). Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response. . Microbes Infect 7:, 1453–1460. [CrossRef].[PubMed].
    [Google Scholar]
  6. Jacob E. , Durham L. C. , Falk M. C. , Williams T. J. , Wheat L. J. . ( 1987; ). Antibody response to teichoic acid and peptidoglycan in Staphylococcus aureus osteomyelitis. . J Clin Microbiol 25:, 122–127.[PubMed].
    [Google Scholar]
  7. Jiang X.-T. , Liu B.-Y. , Zhu P. , Fu N. . ( 2009; ). Production and characterization of a cross-reactive monoclonal antibody to lipopolysaccharide. . Hybridoma (Larchmt) 28:, 93–99. [CrossRef].[PubMed].
    [Google Scholar]
  8. Lin H.-Y. , Tang C.-H. , Chen Y.-H. , Wei I.-H. , Chen J.-H. , Lai C.-H. , Lu D.-Y. . ( 2010; ). Peptidoglycan enhances proinflammatory cytokine expression through the TLR2 receptor, MyD88, phosphatidylinositol 3-kinase/AKT and NF-κB pathways in BV-2 microglia. . Int Immunopharmacol 10:, 883–891. [CrossRef].[PubMed].
    [Google Scholar]
  9. Luo H.-B. , Zheng J. , Zhu P. , Huang L.-Q. , Fu N. . ( 2008; ). Protective immunity induced by peptide mimics to LPS in mice with endotoxic shock. . Prog Inorg Biochem Biophys 35:, 1312–1319.
    [Google Scholar]
  10. MacKenzie S. A. , Roher N. , Boltaña S. , Goetz F. W. . ( 2010; ). Peptidoglycan, not endotoxin, is the key mediator of cytokine gene expression induced in rainbow trout macrophages by crude LPS. . Mol Immunol 47:, 1450–1457. [CrossRef].[PubMed].
    [Google Scholar]
  11. Melzer H. , Baier K. , Felici F. , von Specht B. U. , Wiedermann G. , Kollaritsch H. , Wiedermann U. , Duchêne M. . ( 2003; ). Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. . FEMS Immunol Med Microbiol 37:, 179–183. [CrossRef].[PubMed].
    [Google Scholar]
  12. Merkel G. J. , Scofield B. A. . ( 2001; ). Characterization of a monoclonal antibody that binds to an epitope on soluble bacterial peptidoglycan fragments. . Clin Diagn Lab Immunol 8:, 647–651.[PubMed].
    [Google Scholar]
  13. Minors S. , Horton J. K. , Weeks I. , Davies M. , Coles G. A. . ( 1988; ). A sensitive chemiluminescence based immunoassay for antibody to staphylococcal peptidoglycan. . J Immunol Methods 115:, 119–125. [CrossRef].[PubMed].
    [Google Scholar]
  14. Monzavi-Karbassi B. , Cunto-Amesty G. , Luo P. , Lees A. , Kieber-Emmons T. . ( 2001; ). Immunological characterization of peptide mimetics of carbohydrate antigens in vaccine design strategies. . Biologicals 29:, 249–257. [CrossRef].[PubMed].
    [Google Scholar]
  15. Murphey E. D. , Fang G. , Sherwood E. R. . ( 2008; ). Pretreatment with the Gram-positive bacterial cell wall molecule peptidoglycan improves bacterial clearance and decreases inflammation and mortality in mice challenged with Staphylococcus aureus . . Crit Care Med 36:, 3067–3073. [CrossRef].[PubMed].
    [Google Scholar]
  16. Nozawa T. . ( 1985; ). [Studies on the measurement of antibody to streptococcal cell wall peptidoglycan in rat and human serum using the enzyme-linked immunosorbent assay (ELISA)]. . Nippon Ika Daigaku Zasshi 52:, 521–529 (in Japanese).[PubMed].
    [Google Scholar]
  17. Pashov A. , Monzavi-Karbassi B. , Kieber-Emmons T. . ( 2009; ). Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes. . Vaccine 27:, 3405–3415. [CrossRef].[PubMed].
    [Google Scholar]
  18. Schaffer A. C. , Lee J. C. . ( 2008; ). Vaccination and passive immunisation against Staphylococcus aureus . . Int J Antimicrob Agents 32: Suppl. 1 S71–S78. [CrossRef].[PubMed].
    [Google Scholar]
  19. Schaffer A. C. , Lee J. C. . ( 2009; ). Staphylococcal vaccines and immunotherapies. . Infect Dis Clin North Am 23:, 153–171. [CrossRef].[PubMed].
    [Google Scholar]
  20. Schmaler M. , Jann N. J. , Ferracin F. , Landmann R. . ( 2011; ). T and B cells are not required for clearing Staphylococcus aureus in systemic infection despite a strong TLR2–MyD88-dependent T cell activation. . J Immunol 186:, 443–452. [CrossRef].[PubMed].
    [Google Scholar]
  21. Schuman R. F. , Kokai-Kun J. F. , Foster S. J. , Stinson J. R. , Fischer G. W. . ( 2007; ). Multifunctional Monoclonal Antibodies Directed to Peptidoglycan of Gram-Positive Bacteria. Alexandria, VA:: Official Gazette of the United States Patent and Trademark Office Patents;.
    [Google Scholar]
  22. Spellberg B. , Daum R. S. . ( 2010; ). A new view on development of a Staphylococcus aureus vaccine: insights from mice and men. . Hum Vaccin 6:, 857–859. [CrossRef].[PubMed].
    [Google Scholar]
  23. Styers D. , Sheehan D. J. , Hogan P. , Sahm D. F. . ( 2006; ). Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. . Ann Clin Microbiol Antimicrob 5:, 2. [CrossRef].[PubMed].
    [Google Scholar]
  24. Verbrugh H. A. , Van Dijk W. C. , Peters R. , Van Erne M. E. , Daha M. R. , Peterson P. K. , Verhoef J. . ( 1980; ). Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. . J Immunol 124:, 1167–1173.[PubMed].
    [Google Scholar]
  25. Verbrugh H. A. , Peters R. , Rozenberg-Arska M. , Peterson P. K. , Verhoef J. . ( 1981; ). Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. . J Infect Dis 144:, 1–9. [CrossRef].[PubMed].
    [Google Scholar]
  26. Verbrugh H. A. , Verhoef J. , Wilkinson B. J. , Peterson P. K. . ( 1983; ). Biology and clinical significance of peptidoglycan antibody response in staphylococcal infections. . Scand J Infect Dis Suppl 41:, 117–125.[PubMed].
    [Google Scholar]
  27. Visser L. , De Heer H. J. , Boven L. A. , Van Riel D. , Van Meurs M. , Melief M.-J. , Zähringer U. , Van Strijp J. , Lambrecht B. N. et al. ( 2005; ). Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. . J Immunol 174:, 808–816.[PubMed].[CrossRef]
    [Google Scholar]
  28. Wergeland H. I. , Haaheim L. R. , Natås O. B. , Wesenberg F. , Oeding P. . ( 1989; ). Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections. . J Clin Microbiol 27:, 1286–1291.[PubMed].
    [Google Scholar]
  29. Wheat L. J. , Wilkinson B. J. , Kohler R. B. , White A. C. . ( 1983; ). Antibody response to peptidoglycan during staphylococcal infections. . J Infect Dis 147:, 16–22. [CrossRef].[PubMed].
    [Google Scholar]
  30. Xie W. , Huang Y. , Xie W. , Guo A. , Wu W. . ( 2010; ). Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting Toll-like receptor 2 in the cancer cells. . PLoS ONE 5:, e10850. [CrossRef].[PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.028647-0
Loading
/content/journal/jmm/10.1099/jmm.0.028647-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error